Strategy for effective brain drug delivery.

Blood-brain barrier (BBB) together with enzymes restricts the entry of substances for maintaining the internal milieu of the brain. Because of the presence of multiple endogenous transporters, BBB allows a selective entry of nutrients and minerals across it and limits the entry of foreign substances like drugs as well as neuropharmaceutical agents. This makes the CNS treatment ineffective. The conventional drug delivery systems which release drug into general circulation fail to deliver drugs effectively to brain and is therefore not very useful in treating certain diseases that affect CNS including Alzheimer's disease, dementia, Parkinson's disease, mood disorder, AIDS, viral and bacterial meningitis. Therefore there is a need to develop and design approaches which specifically target to brain in a better and effective way. The present review enlightens about several novel approaches including nanotechnology based approach like nanoparticles, liposomes, antibody mediated delivery approach and application of genomics in brain drug targeting that would give an insight to the researchers, academia and industrialists.

[1]  Sur Sharma,et al.  Advances in antibody-directed enzyme prodrug therapy. , 2005, Current opinion in investigational drugs.

[2]  A. Misra,et al.  Mucoadhesive nanoemulsion-based intranasal drug delivery system of olanzapine for brain targeting , 2008, Journal of drug targeting.

[3]  F. Girardin Membrane transporter proteins: a challenge for CNS drug development , 2006, Dialogues in clinical neuroscience.

[4]  Rakesh K. Sharma,et al.  Delivery of hydrophobised 5-fluorouracil derivative to brain tissue through intravenous route using surface modified nanogels , 2006, Journal of drug targeting.

[5]  Y. Olsson,et al.  Observations on exsudation of fibronectin, fibrinogen and albumin in the brain after carotid infusion of hyperosmolar solutions , 2004, Acta Neuropathologica.

[6]  J. Jankovic,et al.  Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD , 2003, Neurology.

[7]  K. Hynynen,et al.  Use of ultrasound pulses combined with Definity for targeted blood-brain barrier disruption: a feasibility study. , 2007, Ultrasound in Medicine and Biology.

[8]  E. Kohmura,et al.  Basic Fibroblast Growth Factor Prevents Thalamic Degeneration after Cortical Infarction , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[9]  D. Ben-Nathan,et al.  Sodium dodecylsulphate induces a breach in the blood-brain barrier and enables a West Nile virus variant to penetrate into mouse brain , 1989, Brain Research.

[10]  E. Unger,et al.  Therapeutic applications of lipid-coated microbubbles. , 2004, Advanced drug delivery reviews.

[11]  R. Bartus,et al.  The Development of the Bradykinin Agonist Labradimil as a Means to Increase the Permeability of the Blood-Brain Barrier , 2001, Clinical pharmacokinetics.

[12]  B. Engelhardt,et al.  The blood–brain and the blood–cerebrospinal fluid barriers: function and dysfunction , 2009, Seminars in Immunopathology.

[13]  D. A. Kharkevich,et al.  [Transport of the hexapeptide dalargin across the hemato-encephalic barrier into the brain using polymer nanoparticles]. , 1996, Eksperimental'naia i klinicheskaia farmakologiia.

[14]  A. Babbar,et al.  Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. , 2008, International journal of pharmaceutics.

[15]  Xin-guo Jiang,et al.  The brain targeting efficiency following nasally applied MPEG-PLA nanoparticles in rats , 2006, Journal of drug targeting.

[16]  P. Low,et al.  Folate-mediated targeting of therapeutic and imaging agents to cancers. , 1998, Critical reviews in therapeutic drug carrier systems.

[17]  J. Poupaert,et al.  A lymphotropic prodrug of L-dopa: synthesis, pharmacological properties, and pharmacokinetic behavior of 1,3-dihexadecanoyl-2-[(S)-2-amino-3-(3,4-dihydroxyphenyl)prop anoyl] propane-1,2,3-triol. , 1986, Journal of medicinal chemistry.

[18]  Xing Tang,et al.  Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[19]  Y. Olsson,et al.  Structural changes in the rat brain after carotid infusions of hyperosmolar solutions. An electron microscopic study. , 1988, Acta neuropathologica.

[20]  F. Heppner,et al.  Positioning of follicular dendritic cells within the spleen controls prion neuroinvasion , 2003, Nature.

[21]  M A Vandelli,et al.  Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[22]  J. Herms,et al.  Intracarotid administration of short‐chain alkylglycerols for increased delivery of methotrexate to the rat brain , 2003, British journal of pharmacology.

[23]  U. Bickel,et al.  Delivery of peptides and proteins through the blood-brain barrier. , 1993 .

[24]  K. Geiger,et al.  Chemotherapy of glioblastoma in rats using doxorubicin‐loaded nanoparticles , 2004, International journal of cancer.

[25]  H. Wiśniewski,et al.  Scanning and transmission electron microscopic studies of microvascular pathology in the osmotically impaired blood-brain barrier , 1995, Journal of neurocytology.

[26]  Francis C Szoka,et al.  Barriers to carrier mediated drug and gene delivery to brain tumors. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[27]  Tushar K. Vyas,et al.  Improved oral bioavailability and brain transport of Saquinavir upon administration in novel nanoemulsion formulations. , 2008, International journal of pharmaceutics.

[28]  T. Kundu,et al.  Intrinsically fluorescent carbon nanospheres as a nuclear targeting vector: delivery of membrane-impermeable molecule to modulate gene expression in vivo. , 2008, Nano letters.

[29]  Buchwald,et al.  Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems. , 1999, Advanced drug delivery reviews.

[30]  W. Mark Saltzman,et al.  Chemotherapeutic Drugs Released from Polymers: Distribution of 1,3-bis(2-chloroethyl)-l-nitrosourea in the Rat Brain , 1996, Pharmaceutical Research.

[31]  M. Brewster,et al.  The use of chemically modified cyclodextrins in the development of formulations for chemical delivery systems. , 2002, Die Pharmazie.

[32]  W. Löscher,et al.  Blood-brain barrier active efflux transporters: ATP-binding cassette gene family , 2011, NeuroRX.

[33]  W. Pardridge,et al.  Drug and Gene Delivery to the Brain The Vascular Route , 2002, Neuron.

[34]  W. Pardridge Brain drug targeting and gene technologies. , 2001, Japanese journal of pharmacology.

[35]  J. Dean,et al.  The Safety, Tolerability, and Pharmacokinetics of Fosphenytoin after Intramuscular and Intravenous Administration in Neurosurgery Patients , 1996, Pharmacotherapy.

[36]  Vanessa S. Rothholtz,et al.  Comparison of cytosine arabinoside delivery to rat brain by intravenous, intrathecal, intraventricular and intraparenchymal routes of administration , 2000, Brain Research.

[37]  Aaron P. Campbell,et al.  Suppression subtractive hybridization: a method for generating differentially regulated or tissue-specific cDNA probes and libraries. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[38]  W. Saltzman,et al.  Pharmacokinetics of the Carmustine Implant , 2002, Clinical pharmacokinetics.

[39]  Jie Ren,et al.  Preparation and Therapeutic Efficacy of Polysorbate-80-Coated Amphotericin B/PLA-b-PEG Nanoparticles , 2009, Journal of biomaterials science. Polymer edition.

[40]  E. Chiocca,et al.  Intraarterial delivery of adenovirus vectors and liposome-DNA complexes to experimental brain neoplasms. , 1999, Human gene therapy.

[41]  E. Neuwelt,et al.  An exploratory study of ferumoxtran-10 nanoparticles as a blood-brain barrier imaging agent targeting phagocytic cells in CNS inflammatory lesions. , 2005, AJNR. American journal of neuroradiology.

[42]  Jie Pan,et al.  Targeted delivery of paclitaxel using folate-decorated poly(lactide)-vitamin E TPGS nanoparticles. , 2008, Biomaterials.

[43]  M. Samanta,et al.  Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[44]  R. Sharma,et al.  Influence of administration route on tumor uptake and biodistribution of etoposide loaded solid lipid nanoparticles in Dalton's lymphoma tumor bearing mice. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[45]  R. Kim,et al.  Blood−brain barrier transporters and response to CNS-active drugs , 2009, European Journal of Clinical Pharmacology.

[46]  N. Savaraj,et al.  Pharmacology of intrathecal VP-16-213 in dogs , 1992, Journal of Neuro-Oncology.

[47]  R. Brakenhoff,et al.  Construction and characterization of a fusion protein of single-chain anti-CD20 antibody and human beta-glucuronidase for antibody-directed enzyme prodrug therapy. , 1998, Blood.

[48]  Qing Wang,et al.  Intranasal administration with NAD+ profoundly decreases brain injury in a rat model of transient focal ischemia. , 2007, Frontiers in bioscience : a journal and virtual library.

[49]  E. Björk,et al.  Direct Nose-to-Brain Transfer of Morphine After Nasal Administration to Rats , 2006, Pharmaceutical Research.

[50]  A. Dalpiaz,et al.  Progress in Drug Delivery to the Central Nervous System by the Prodrug Approach , 2008, Molecules.

[51]  K. Waku,et al.  2-Arachidonoylglycerol and anandamide oppositely modulate norepinephrine release from the rat heart sympathetic nerves. , 2001, Japanese journal of pharmacology.

[52]  Y. Cai,et al.  Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[53]  Keith L Black,et al.  Modulation of brain tumor capillaries for enhanced drug delivery selectively to brain tumor. , 2004, Cancer control : journal of the Moffitt Cancer Center.

[54]  D. Geschwind,et al.  Disruption of Astrocyte STAT3 Signaling Decreases Mitochondrial Function and Increases Oxidative Stress In Vitro , 2010, PloS one.

[55]  Lei Zhang,et al.  Gum Arabic-Coated Magnetic Nanoparticles for Potential Application in Simultaneous Magnetic Targeting and Tumor Imaging , 2009, The AAPS Journal.

[56]  Targeting drugs to the brain by redox chemical delivery systems , 2000, Medicinal research reviews.

[57]  W. Pardridge Vector-mediated peptide drug delivery to the brain. , 1995, Advanced drug delivery reviews.

[58]  Bhavna,et al.  Potential of nanoparticulate drug delivery systems by intranasal administration. , 2010, Current pharmaceutical design.

[59]  J. M. Beals,et al.  Assembly and Dissociation of Human Insulin and LysB28ProB29-Insulin Hexamers: A Comparison Study , 2004, Pharmaceutical Research.

[60]  W. Pardridge,et al.  Human Insulin Receptor Monoclonal Antibody Undergoes High Affinity Binding to Human Brain Capillaries in Vitro and Rapid Transcytosis Through the Blood–Brain Barrier in Vivo in the Primate , 1995, Pharmaceutical Research.

[61]  W. Pardridge,et al.  Human blood-brain barrier insulin-like growth factor receptor. , 1988, Metabolism: clinical and experimental.

[62]  J. Kreuter,et al.  Significant Transport of Doxorubicin into the Brain with Polysorbate 80-Coated Nanoparticles , 1999, Pharmaceutical Research.

[63]  D. A. Kharkevich,et al.  Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study. , 1998, Journal of microencapsulation.

[64]  H. Steinbusch,et al.  Delivery of peptide and protein drugs over the blood–brain barrier , 2009, Progress in Neurobiology.

[65]  R. Sherwood,et al.  Antibody-enzyme conjugates for cancer therapy. , 1996, Journal of the National Cancer Institute.

[66]  Gary M Pollack,et al.  Nasal drug administration: potential for targeted central nervous system delivery. , 2005, Journal of pharmaceutical sciences.

[67]  J. Benoit,et al.  Development of microspheres for neurological disorders: from basics to clinical applications. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[68]  M. Lakomek,et al.  Increased delivery of erucylphosphocholine to C6 gliomas by chemical opening of the blood-brain barrier using intracarotid pentylglycerol in rats , 2002, Cancer Chemotherapy and Pharmacology.

[69]  R. Müller,et al.  The role of apolipoprotein E in uptake of atovaquone into the brain in murine acute and reactivated toxoplasmosis , 2009, Journal of drug targeting.

[70]  A. Samad,et al.  Liposomal drug delivery systems: an update review. , 2007, Current drug delivery.

[71]  Kullervo Hynynen,et al.  Ultrasound for drug and gene delivery to the brain. , 2008, Advanced drug delivery reviews.

[72]  Kinam Park Transport across the blood-brain barrier using albumin nanoparticles. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[73]  R. Spooner,et al.  Genetic delivery of enzymes for cancer therapy. , 1995, Gene therapy.

[74]  N. Bodor,et al.  Facile, One-Step Preparation of Trigonellinate Esters , 1987 .

[75]  H. Wakimoto,et al.  Intra-arterial delivery of p53-containing adenoviral vector into experimental brain tumors , 2002, Cancer Gene Therapy.

[76]  Xin-guo Jiang,et al.  From nose to brain: understanding transport capacity and transport rate of drugs , 2008, Expert opinion on drug delivery.

[77]  L. Illum Transport of drugs from the nasal cavity to the central nervous system. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[78]  F. Balis,et al.  Plasma and Cerebrospinal Fluid Pharmacokinetics of Intravenous Temozolomide in Non-human Primates , 2003, Journal of Neuro-Oncology.

[79]  W. Pardridge,et al.  Brain-specific expression of an exogenous gene after i.v. administration , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[80]  S. Sheleg,et al.  Local Chemotherapy with Cisplatin-depot for Glioblastoma Multiforme , 2002, Journal of Neuro-Oncology.

[81]  G. T. Cottrell,et al.  Sensory circumventricular organs: central roles in integrated autonomic regulation , 2004, Regulatory Peptides.

[82]  J. Lawrenson,et al.  Pericytes: Cell Biology and Pathology , 2001, Cells Tissues Organs.

[83]  H. Brem,et al.  Biodegradable polymer implants to treat brain tumors. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[84]  B. Sabel,et al.  Nanoparticle technology for delivery of drugs across the blood-brain barrier. , 1998, Journal of pharmaceutical sciences.

[85]  J. Ghersi-Egea,et al.  The Role of the Choroid Plexus in Neutrophil Invasion after Traumatic Brain Injury , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[86]  Tushar K. Vyas,et al.  Cytotoxicity and apoptosis enhancement in brain tumor cells upon coadministration of paclitaxel and ceramide in nanoemulsion formulations. , 2008, Journal of pharmaceutical sciences.

[87]  M. Bally,et al.  A two-step targeting approach for delivery of doxorubicin-loaded liposomes to tumour cells in vivo , 2004, Cancer Chemotherapy and Pharmacology.

[88]  N. Zhang,et al.  Solid lipid nanoparticles of temozolomide: potential reduction of cardial and nephric toxicity. , 2008, International journal of pharmaceutics.

[89]  J M Scherrmann,et al.  Drug delivery to brain via the blood-brain barrier. , 2002, Vascular pharmacology.

[90]  H. Gendelman,et al.  Macrophage Delivery of Nanoformulated Antiretroviral Drug to the Brain in a Murine Model of NeuroAIDS1 , 2009, The Journal of Immunology.

[91]  E. Brittebo,et al.  Transfer of morphine along the olfactory pathway to the central nervous system after nasal administration to rodents. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[92]  A. Carpentier Neuro-oncology: the growing role of chemotherapy in glioma , 2005, The Lancet Neurology.

[93]  S. Piantadosi,et al.  Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas , 1995, The Lancet.

[94]  A. Lackner,et al.  Simian immunodeficiency virus disrupts extended lengths of the blood–brain barrier , 2005, Journal of medical primatology.

[95]  D. Kopacz,et al.  Extended-Duration Analgesia: Update on Microspheres and Liposomes , 2005, Regional Anesthesia & Pain Medicine.

[96]  T. Stockley,et al.  The in vivo delivery of heterologous proteins by microencapsulated recombinant cells. , 1999, Trends in biotechnology.

[97]  Andrew Baird,et al.  Enhanced Prospects for Drug Delivery and Brain Targeting by the Choroid Plexus–CSF Route , 2005, Pharmaceutical Research.

[98]  D. A. Kharkevich,et al.  Analgesic activity of the hexapeptide dalargin adsorbed on the surface of polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles , 1995 .

[99]  G. Amidon,et al.  Peptide-based Drug Design, Controlling Transport and Metabolism , 1995 .

[100]  W. Saltzman,et al.  Controlled release of proteins to tissue transplants for the treatment of neurodegenerative disorders. , 1996, Journal of pharmaceutical sciences.

[101]  D. A. Kharkevich,et al.  Delivery of Loperamide Across the Blood-Brain Barrier with Polysorbate 80-Coated Polybutylcyanoacrylate Nanoparticles , 1997, Pharmaceutical Research.

[102]  Alexander V Kabanov,et al.  Nanogels for oligonucleotide delivery to the brain. , 2004, Bioconjugate chemistry.

[103]  Thomas Wirth,et al.  Three-step tumor targeting of paclitaxel using biotinylated PLA-PEG nanoparticles and avidin-biotin technology: Formulation development and in vitro anticancer activity. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[104]  Xun Sun,et al.  Enhanced brain targeting by synthesis of 3',5'-dioctanoyl-5-fluoro-2'-deoxyuridine and incorporation into solid lipid nanoparticles. , 2002, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[105]  T Sinkjaer,et al.  Interfacing the body's own sensing receptors into neural prosthesis devices. , 1999, Technology and health care : official journal of the European Society for Engineering and Medicine.

[106]  E. Barbu,et al.  The potential for nanoparticle-based drug delivery to the brain: overcoming the blood–brain barrier , 2009 .

[107]  D. Crommelin,et al.  A new application for liposomes in cancer therapy , 1993, FEBS letters.

[108]  D. Tzemach,et al.  Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals , 1997 .

[109]  Stanley B. Prusiner,et al.  Nobel Lecture: Prions , 1998 .

[110]  G. Tosi,et al.  Nanoparticles as drug delivery agents specific for CNS: in vivo biodistribution. , 2009, Nanomedicine : nanotechnology, biology, and medicine.

[111]  J. Gomori,et al.  Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood‐brain barrier disruption in patients with brain lymphoma , 2000, Clinical pharmacology and therapeutics.

[112]  Theresa M. Allen,et al.  Pharmacokinetics of long-circulating liposomes , 1995 .

[113]  W. Banks,et al.  Delivery of Galanin-Like Peptide to the Brain: Targeting with Intranasal Delivery and Cyclodextrins , 2008, Journal of Pharmacology and Experimental Therapeutics.

[114]  R. Egleton,et al.  Development of neuropeptide drugs that cross the blood-brain barrier , 2011, NeuroRX.

[115]  R. Puri,et al.  Distribution kinetics of targeted cytotoxin in glioma by bolus or convection-enhanced delivery in a murine model. , 2004, Journal of neurosurgery.

[116]  W. Pardridge Blood-brain barrier drug targeting: the future of brain drug development. , 2003, Molecular interventions.

[117]  P. Kennedy,et al.  Restoration of neural output from a paralyzed patient by a direct brain connection , 1998, Neuroreport.

[118]  Lisbeth Illum,et al.  Nanoparticles for direct nose-to-brain delivery of drugs. , 2009, International journal of pharmaceutics.

[119]  E. De Clercq,et al.  Targeting of antiviral drugs to T4-lymphocytes. Anti-HIV activity of neoglycoprotein-AZTMP conjugates in vitro. , 1990, Biochemical pharmacology.

[120]  W. Frey,et al.  Intranasal administration of a PARG inhibitor profoundly decreases ischemic brain injury. , 2007, Frontiers in bioscience : a journal and virtual library.

[121]  C. Crone,et al.  Electrical resistance of a capillary endothelium , 1981, The Journal of general physiology.

[122]  A. Ommaya Implantable devices for chronic access and drug delivery to the central nervous system. , 1984, Cancer drug delivery.

[123]  J. Pandit,et al.  Controlled release formulations in neurology practice , 2006 .

[124]  D. Murry,et al.  Clinical Pharmacology of Encapsulated Sustained-Release Cytarabine , 2000, The Annals of pharmacotherapy.

[125]  W. Pardridge,et al.  Imaging endogenous gene expression in brain cancer in vivo with 111In-peptide nucleic acid antisense radiopharmaceuticals and brain drug-targeting technology. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[126]  W. Pardridge,et al.  Blood-brain barrier delivery. , 2007, Drug discovery today.

[127]  B. Swartz,et al.  The Human Brain GLUT1 Glucose Transporter: Ultrastructural Localization to the Blood—Brain Barrier Endothelia , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[128]  E. Brittebo,et al.  Transfer of Dopamine in the Olfactory Pathway Following Nasal Administration in Mice , 2000, Pharmaceutical Research.

[129]  C. Borlongan,et al.  Facilitation of drug entry into the CNS via transient permeation of blood brain barrier: laboratory and preliminary clinical evidence from bradykinin receptor agonist, Cereport , 2003, Brain Research Bulletin.

[130]  K. Frei,et al.  Molecular and cellular permeability control at the blood–brain barrier , 2001, Brain Research Reviews.

[131]  Shailendra Joshi,et al.  Enhanced Disruption of the Blood Brain Barrier by Intracarotid Mannitol Injection During Transient Cerebral Hypoperfusion in Rabbits , 2007, Journal of neurosurgical anesthesiology.

[132]  Alexander Sasha Rabchevsky,et al.  Peripheral injections of Freund's adjuvant in mice provoke leakage of serum proteins through the blood–brain barrier without inducing reactive gliosis , 1999, Brain Research.

[133]  Paul R. Lockman,et al.  Nanoparticle Surface Charges Alter Blood–Brain Barrier Integrity and Permeability , 2004, Journal of drug targeting.

[134]  S. Schwarze,et al.  In vivo protein transduction: delivery of a biologically active protein into the mouse. , 1999, Science.

[135]  James L. Frazier,et al.  Local drug delivery to the brain. , 2002, Advanced drug delivery reviews.

[136]  W. Pardridge,et al.  A Direct In Vitro Demonstration of Insulin Binding to Isolated Brain Microvessels , 1981, Diabetes.

[137]  D. Begley Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. , 2004, Pharmacology & therapeutics.

[138]  P. Yeole,et al.  Brain targeting studies on buspirone hydrochloride after intranasal administration of mucoadhesive formulation in rats , 2009, The Journal of pharmacy and pharmacology.

[139]  W. Pardridge,et al.  Conjugation of brain-derived neurotrophic factor to a blood–brain barrier drug targeting system enables neuroprotection in regional brain ischemia following intravenous injection of the neurotrophin , 2001, Brain Research.

[140]  Y. Kanai,et al.  Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition. , 2002, Molecular pharmacology.

[141]  W. Pardridge,et al.  Blood—Brain Barrier Genomics , 2001, Methods in molecular medicine.

[142]  K Hynynen,et al.  Histologic effects of high intensity pulsed ultrasound exposure with subharmonic emission in rabbit brain in vivo. , 1995, Ultrasound in medicine & biology.

[143]  W. Pardridge The blood-brain barrier and neurotherapeutics , 2011, NeuroRX.

[144]  S. Olesen,et al.  Electrical resistance of brain microvascular endothelium , 1982, Brain Research.

[145]  W. Pardridge,et al.  Epidermal growth factor radiopharmaceuticals: 111In chelation, conjugation to a blood-brain barrier delivery vector via a biotin-polyethylene linker, pharmacokinetics, and in vivo imaging of experimental brain tumors. , 1999, Bioconjugate chemistry.

[146]  R. Sharma,et al.  Preliminary brain-targeting studies on intranasal mucoadhesive microemulsions of sumatriptan , 2006, AAPS PharmSciTech.

[147]  Jarkko Rautioa,et al.  Drug delivery systems for brain tumor therapy. , 2004, Current pharmaceutical design.

[148]  W. Risau Differentiation of endothelium , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[149]  G. Vassal,et al.  Poly(ethylene glycol)-Coated Hexadecylcyanoacrylate Nanospheres Display a Combined Effect for Brain Tumor Targeting , 2002, Journal of Pharmacology and Experimental Therapeutics.

[150]  T. Davis,et al.  The Blood-Brain Barrier/Neurovascular Unit in Health and Disease , 2005, Pharmacological Reviews.

[151]  B. Zlokovic,et al.  Differential expression of Na,K-ATPase alpha and beta subunit isoforms at the blood-brain barrier and the choroid plexus. , 1993, The Journal of biological chemistry.

[152]  A. Tsuji Influx transporters and drug targeting: Application of peptide and cation transporters , 2005 .

[153]  S. Davis,et al.  The organ uptake of intravenously administered colloidal particles can be altered using a non‐ionic surfactant (Poloxamer 338) , 1984, FEBS letters.

[154]  E. Lo,et al.  Drug delivery to damaged brain , 2001, Brain Research Reviews.

[155]  L. Illum,et al.  Intranasal delivery: physicochemical and therapeutic aspects. , 2007, International journal of pharmaceutics.

[156]  C. Springer,et al.  Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[157]  F. Szoka,et al.  Distribution in brain of liposomes after convection enhanced delivery; modulation by particle charge, particle diameter, and presence of steric coating , 2005, Brain Research.

[158]  T. Terasaki,et al.  Drug delivery to the brain utilizing blood-brain barrier transport systems , 1994 .

[159]  A. Małecki,et al.  Physiology and pharmacological role of the blood-brain barrier. , 2008, Pharmacological reports : PR.

[160]  W. Pardridge,et al.  Global non-viral gene transfer to the primate brain following intravenous administration. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[161]  J. Huwyler,et al.  Drug transport to brain with targeted liposomes , 2011, NeuroRX.

[162]  R. Egleton,et al.  Bioavailability and Transport of Peptides and Peptide Drugs into the Brain , 1997, Peptides.

[163]  S. Rapoport Osmotic Opening of the Blood–Brain Barrier: Principles, Mechanism, and Therapeutic Applications , 2000, Cellular and Molecular Neurobiology.

[164]  G. Hocking,et al.  Intrathecal drug spread. , 2004, British journal of anaesthesia.

[165]  M. Hashida,et al.  The effect of polysorbate 80 on brain uptake and analgesic effect of D-kyotorphin , 1989 .

[166]  M. McGirt,et al.  Use of Gliadel (BCNU) Wafer in the Surgical Treatment of Malignant Glioma: A 10-Year Institutional Experience , 2008, Annals of Surgical Oncology.

[167]  C. Nicholson,et al.  Extracellular space structure revealed by diffusion analysis , 1998, Trends in Neurosciences.

[168]  A. Sigal,et al.  Pegylated nanoliposomes remote-loaded with the antioxidant tempamine ameliorate experimental autoimmune encephalomyelitis , 2009, Journal of Neuroimmunology.

[169]  R. Motter,et al.  Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.

[170]  W. Pardridge,et al.  Imaging brain tumors by targeting peptide radiopharmaceuticals through the blood-brain barrier. , 1999, Cancer research.

[171]  P. Senter Activation of prodrugs by antibody‐enzyme conjugates: a new approach to cancer therapy , 1990, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[172]  K. Fritze,et al.  Effect of global system for mobile communication (GSM) microwave exposure on blood-brain barrier permeability in rat , 1997, Acta Neuropathologica.

[173]  K. Hynynen,et al.  MRI investigation of the threshold for thermally induced blood–brain barrier disruption and brain tissue damage in the rabbit brain , 2004, Magnetic resonance in medicine.

[174]  I. Rubinstein,et al.  Role of nanotechnology in targeted drug delivery and imaging: a concise review. , 2005, Nanomedicine : nanotechnology, biology, and medicine.